In the most recent ongoing phase II trial (The DEBBRAH trial), one cohort of patients included both HER-2 + and HER-2 low breast cancer patients presenting with asymptomatic and untreated BM showed ORR- intracranial (IC) of 50%. Here, ERBB2 is linked to breast carcinoma.